EGFR and neoplasm: No gender-related prognostic heterogeneity was observed in other subgroups, including age, tumor location, T stage, pathological type, bone/lung/liver metastasis, chemotherapy, radiotherapy, AAT therapy, EGFR-TKI treatment, or ICIs treatment (P > 0.05).